Immunomedics is a leader in next-generation antibody-drug conjugate (ADC) technology, committed
to helping transform the lives of people with hard-to-treat cancers. Our proprietary ADC binds to
Trop-2-expressing cancer cells and is internalized with the subsequent release of SN-38 via hydrolysis
of the linker. SN-38 interacts with topoisomerase I and prevents re-ligation of topoisomerase I-induced
single strand breaks. For additional information about Immunomedics or to contact Medical Affairs, please
visit our website, Immunomedics.com. When you click to view product literature below, Immunomedics
will make a $25 donation to the TNBC Foundation.